VivoSeq
Other

Graves Disease

19

Pipeline Programs↗

19

Active Trials↗

12

Companies Involved↗

Graves disease is an emerging landscape with 19 programs across 12 companies. The most active players are Merida Biosciences, Yarrow Bioscience, Inc., Sanofi. 5 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

39/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Merida Biosciences

6 programs

Phase 1Y

Yarrow Bioscience, Inc.

2 programs

Phase 2Sanofi logo

Sanofi

2 programs

Phase 2B

Biohaven Therapeutics Ltd.

1 program

Phase 3Argenx logo

Argenx

1 program

Phase 3D

Dawnrays Pharmaceutical (Holdings) Limited

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

34

clinical trials

Recruiting18 · 53%
Completed13 · 38%
Unknown status2 · 6%
Enrolling by invitation1 · 3%

Clinical Trials

Trial Activity

34 trials

Study of BHV-1300 in Graves' Disease
Recruiting·BBiohaven Therapeutics Ltd.·Phase 1·NCT06980649·15 enrolled
A Study of GensSci098 in Subjects With Graves' Disease
Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd. logoChangchun GeneScience Pharmaceutical Co., Ltd.·Phase 1·NCT07286656·24 enrolled
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05461820·240 enrolled
Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
Recruiting·NNorthwell Health·Phase 2·NCT07369063·30 enrolled
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
Recruiting·SShanghai Zhongshan Hospital·Phase 1·NCT07129642·5 enrolled
Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter
Recruiting·—·Phase 3·NCT04856488·182 enrolled
A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
Recruiting·FFirst Hospital of China Medical University·N/A·NCT07040306·1,000 enrolled
In Vivo CAR-T for Refractory Graves' Disease
Recruiting·SShanghai Zhongshan Hospital·Phase 1·NCT07333677·5 enrolled
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
Recruiting·SShanghai Zhongshan Hospital·Phase 1·NCT07261345·4 enrolled
Graves' Disease Remission Study: MycoMeth Combo
Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2/3·NCT06068179·205 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06727604·240 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Recruiting·IImmunovant Sciences GmbH·Phase 2·NCT07018323·210 enrolled
A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease
Recruiting·BBiohaven Therapeutics Ltd.·Phase 3·NCT07661056·300 enrolled
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
Recruiting·Argenx logoArgenx·Phase 3·NCT07596849·230 enrolled
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
Recruiting·Argenx logoArgenx·Phase 3·NCT07570316·230 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)